According to the official website, the formula contains berberine (from Berberis aristata bark powder), zinc, Polygonum cuspidatum extract, and quercetin dihydrate
This may contributes partly to the growth retardation in children and adolescents with low riboflavin intake
Continued research led to the first GLP-1 drugs approved for weight loss in people with obesity or overweight: liraglutide or Saxenda in 2014, semaglutide as Wagovy in 2021 and tirzepatide as Zepbound in 2023
In these trials, participants achieved a mean weight loss of approximately 15% of body weight over 68 weeks-correlating with a substantial calorie deficit that contributes to initial fatigue
It provides an in-depth assessment of the effectiveness of GLP-1RAs across multiple body systems-including the nervous, cardiovascular, musculoskeletal, and digestive systems